Preliminary data from SOAP trial suggests low response to first dose of Pfizer-BioNTech Covid-19 vaccine in patients with cancer
The preliminary report (not peer reviewed) states antibody responses 3 weeks following the first vaccine dose were 39% in those with solid cancers (SC) and 13% in haematological cancers (HC). When a booster was given at 3 weeks, efficacy was 95% in SC (inadequate data for HC).
Source:
King’s College London
SPS commentary:
The SOAP trial enrolled 151 cancer patients and 54 healthy controls. It will continue to follow patients post-vaccination for up to 6 months